ACRX earnings call for the period ending March 31, 2019.
News & Analysis: AcelRx Pharmaceuticals
The pharma announced first-quarter 2019 operating results.
They could be big winners for patient investors.
Investors wanted more good news than they got in the specialty-drug maker's fourth-quarter update.
These three small-cap stocks have outstanding growth potential.
AcelRx and Novavax are two penny biotech stocks worth checking out in this latest market downturn.
When you invest in a business, you should expect to stay with it for the long haul.
After earning FDA marketing approval for a controversial new drug, the company is raising cash through a share offering.
Nothing to worry about after the biotech received a much-needed FDA approval last week.
With new drug applications under review at the moment, these 3 biotech stocks could surge in the weeks ahead.